Endocyte to Present at the IASLC 17th World Conference on Lung Cancer
December 01 2016 - 8:01AM
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small
molecule drug conjugates (SMDCs) and companion imaging agents for
personalized therapy, today announced that data from ongoing phase
1 trials of Endocyte’s SMDC EC1456 will be presented at the IASLC
17th World Conference on Lung Cancer on Wednesday, Dec. 7, at 2:30
P.M. CET. The conference will be held at the Messe Wien Exhibition
& Congress Center in Vienna, Austria.
The presentation will be available on Endocyte’s website
following presentation at the conference.
Presentation is as follows:
Poster
Presentation: |
|
Phase 1 Dose Escalation, Safety and Pharmacokinetic Study of
the Folate Receptor-Targeted Small Molecule Drug Conjugate (SMDC)
EC1456 in Advanced Cancer: Lung Cancer Patient Subset |
When: |
|
Wednesday, December 7th, 2:30 p.m. – 3:45 p.m. CET, Hall B |
Track: |
|
Advanced NSCLC |
Presenter: |
|
Martin J.
Edelman, University of Maryland Greenebaum Cancer Center,
Baltimore |
About EC1456 and
etarfolatide
EC1456 is an investigational therapeutic SMDC constructed of
folic acid conjugated through a spacer and releasable linker system
to a potent cytotoxic microtubule inhibitor, TubBH. The high
affinity of the folic acid ligand for the FR allows for the active
and specific targeting of EC1456 to FR-expressing cancer
cells. The FR is highly expressed in several epithelial
cancers (e.g. ovarian, NSCLC) but is expressed at low levels in
most normal tissues.
Etarfolatide is an FR-targeted companion imaging agent being
co-developed to characterize whole body FR expression in real time,
to identify patients most likely to benefit from EC1456
therapy. EC1456 and etarfolatide are currently being
evaluated in a phase 1 study in patients with advanced solid tumors
(ClinicalTrials.gov Identifier: NCT01999738).
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the treatment of cancer and other serious
diseases. Endocyte uses its proprietary drug conjugation
technology to create novel SMDCs and companion imaging agents for
personalized targeted therapies. The company’s SMDCs actively
target receptors that are over-expressed on diseased cells relative
to healthy cells. This targeted approach is designed to
enable the treatment of patients with highly active drugs at
greater doses, delivered more frequently and over longer periods of
time than would be possible with the untargeted drug alone.
The companion imaging agents are designed to identify patients
whose disease over-expresses the target of the therapy and who are
therefore more likely to benefit from treatment. For additional
information, please visit Endocyte’s website at
www.endocyte.com.
Contacts:
Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, michael@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Sep 2023 to Sep 2024